Shares of Epizyme (NASDAQ:EPZM) have been assigned a consensus rating of “Buy” from the sixteen brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $23.64.
A number of brokerages have weighed in on EPZM. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Roth Capital began coverage on Epizyme in a research note on Thursday, February 1st. They set a “buy” rating and a $24.00 price objective for the company. Oppenheimer set a $26.00 price objective on Epizyme and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd.
NASDAQ EPZM traded up $0.87 during mid-day trading on Thursday, reaching $14.65. 440,953 shares of the company’s stock traded hands, compared to its average volume of 449,519. Epizyme has a 1-year low of $9.30 and a 1-year high of $21.40. The firm has a market cap of $1,031.80, a PE ratio of -6.83 and a beta of 1.95.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the transaction, the chief operating officer now owns 74,867 shares of the company’s stock, valued at approximately $1,245,038.21. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 25.20% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas bought a new stake in shares of Epizyme in the 4th quarter worth approximately $202,000. Fox Run Management L.L.C. lifted its holdings in shares of Epizyme by 64.7% in the 4th quarter. Fox Run Management L.L.C. now owns 19,275 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 7,575 shares during the last quarter. Bailard Inc. bought a new stake in shares of Epizyme in the 4th quarter worth approximately $251,000. MetLife Investment Advisors LLC bought a new stake in shares of Epizyme in the 4th quarter worth approximately $263,000. Finally, Virtus Fund Advisers LLC bought a new stake in shares of Epizyme in the 4th quarter worth approximately $346,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Analysts Set Epizyme (EPZM) PT at $23.64” was first published by Week Herald and is owned by of Week Herald. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://weekherald.com/2018/04/17/analysts-set-epizyme-epzm-pt-at-23-64.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.